BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18639338)

  • 1. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
    Neumann F; Gattermann N; Barthelmes HU; Haas R; Germing U
    Leuk Res; 2009 Feb; 33(2):232-6. PubMed ID: 18639338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myelodysplastic syndrome--a retrospective study of 38 patients].
    Schrappe-Bächer M; Steffen HM; Maier M; Bernards P; Hoeffken A; Fätkenheuer G
    Med Klin (Munich); 1990 Sep; 85(9):511-6. PubMed ID: 2233608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
    Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
    Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
    Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith TL; Rios MB; Kantarjian H
    Clin Cancer Res; 2000 Jan; 6(1):147-52. PubMed ID: 10656443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes in patients under 50 years old: a single institution experience.
    Breccia M; Mengarelli A; Mancini M; Biondo F; Gentilini F; Latagliata R; Mandelli F; Alimena G
    Leuk Res; 2005 Jul; 29(7):749-54. PubMed ID: 15927670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Hock BD; McKenzie JL; Patton WN; Haring LF; Yang Y; Shen Y; Estey EH; Albitar M
    Cancer; 2003 Oct; 98(8):1681-8. PubMed ID: 14534885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
    Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
    Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
    Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
    Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
    Hui CH; Horvath N; Lewis I; To LB; Szabo F
    Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase activity in myelodysplastic syndromes.
    Gürkan E; Tanriverdi K; Başlamişli F
    Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
    Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
    Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome].
    Aul C; Germing U; Gattermann N; Söhngen D; Heyll A
    Dtsch Med Wochenschr; 1996 Sep; 121(37):1113-8. PubMed ID: 8925725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.
    Breccia M; Mancini M; Nanni M; D'Elia GM; Carmosino I; Latagliata R; Sarlo C; Mandelli F; Alimena G
    Leuk Res; 2005 Jan; 29(1):33-9. PubMed ID: 15541472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).
    Gatto S; Ball G; Onida F; Kantarjian HM; Estey EH; Beran M
    Blood; 2003 Sep; 102(5):1622-5. PubMed ID: 12738677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
    Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
    Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
    Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
    Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
    Travaglino E; Benatti C; Malcovati L; Della Porta MG; Gallì A; Bonetti E; Rosti V; Cazzola M; Invernizzi R
    Eur J Haematol; 2008 Mar; 80(3):216-26. PubMed ID: 18081721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
    Sieglová Z; Zilovcová S; Cermák J; Ríhová H; Brezinová D; Dvoráková R; Marková M; Maaloufová J; Sajdová J; Brezinová J; Zemanová Z; Michalová K
    Leuk Res; 2004 Oct; 28(10):1013-21. PubMed ID: 15289012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
    Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
    Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.